Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key ...

While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, ...

Switzerland's Ferring Pharma has reached an agreement to buy US women's health startup Gameto for up to $1.38 billion, ...

Sweden's Egetis Therapeutics has launched the first-ever treatment for people living with the ultra-rare genetic disease MCT8 ...

The Novartis Pavillon in Park South of the Novartis Campus in Basel, Switzerland. Novartis's third-quarter results included a ...

There is a moment, somewhere in a pharma content workflow, when a draft stops being a draft and becomes an action – sent, ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO tomorrow, after a data embargo breach. The INTerpath-001 in patients with ...

A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger. The latest – which includes an upfront fee of $400 ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by 2nd February next year. If approved, the oral ...

Novo filed its lawsuit in the summer, accusing Lilly of a "nationwide pattern of deceptive advertising" for its obesity ...